PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|February 22, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-03-02-2016
- Volume 11
- Issue 3
Patheon Signs Strategic Agreement with Grünenthal
Author(s)Pharmaceutical Technology Editors
Patheon will assist in the development of INTAC, a technology designed to reduce the abuse of controlled substances.
Advertisement
On Feb. 22, 2016 Patheon announced it has signed a strategic agreement with Grünenthal, an international research-based pharmaceutical group headquartered in Aachen, Germany, to serve as its preferred development partner for its products made using Grünenthal’s abuse deterrent formulation technology INTAC.
Patheon was selected to assist with the development of advanced INTAC based products including single-entity and fixed-dose combination solid oral dosage forms with immediate and modified release properties. INTAC is Grünenthal’s proprietary technology designed to reduce the potential for abuse of controlled substances.
INTAC is an abuse-deterrent formulation technology platform, used with several FDA-approved opioid products. As part of the agreement, Grünenthal has agreed to install specialized equipment in Patheon’s Cincinnati manufacturing site.
Source: Patheon
Articles in this issue
over 10 years ago
Small-Scale Modeling Boosts Downstream Developmentover 10 years ago
Technologies Expand Horizons of the Analytical Labover 10 years ago
Global Conflicts and CMO Impactsover 10 years ago
Hazardous Reagents for Higher Yieldsover 10 years ago
Mechanical Pipettes Have Ergonomic Designover 10 years ago
Benchtop Centrifuge Features Hybrid Rotorover 10 years ago
Cirrus Pharmaceuticals Announces Manufacturing for Clinical Trialsover 10 years ago
ICIG Acquires Sandoz Site in Germanyover 10 years ago
Recipharm Acquires Italian CDMOAdvertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Advertisement
Advertisement